Latest Conference Articles

April 28th 2020, 4:01am

AACR Annual Meeting

The addition of durvalumab (Imfinzi) and olaparib (Lynparza) to neoadjuvant paclitaxel was found to improve pathologic complete response rates compared with paclitaxel alone in patients with high-risk, HER2-negative stage II/III breast cancer.

April 28th 2020, 3:01am

AACR Annual Meeting

Patients with pretreated non–small cell lung cancer and EGFR exon 20 insertions demonstrated a 68.7% disease control rate while on poziotinib systemic therapy.

April 28th 2020, 3:00am

AACR Annual Meeting

Results from the GEOMETRY mono-1 study demonstrated antitumor efficacy of and deep and durable responses with capmatinib in 97 patients with advanced non–small cell lung cancer who harbor MET exon 14 mutations.

April 28th 2020, 2:25am

AACR Annual Meeting

Treatment with talazoparib did not demonstrate a statistically significant overall survival benefit in patients with BRCA1/2-mutated metastatic HER2-negative breast cancer.

April 28th 2020, 1:41am

AACR Annual Meeting

Treatment with atezolizumab in combination with vemurafenib and cobimetinib was found to significantly improve progression-free survival and produce durable responses versus vemurafenib and cobimetinib alone in treatment-naïve patients with BRAF V600–mutant advanced melanoma.

April 28th 2020, 1:28am

AACR Annual Meeting

Michael J. Thirman, MD, discusses the clinical rationale for using the investigational agent SNDX-5613 to treat a subtype of acute myeloid leukemia and acute lymphoblastic leukemia.

April 28th 2020, 1:23am

AACR Annual Meeting

Andrea Wang-Gillam, MD, PhD, discusses the results of a phase 1 study with defactinib in patients with pancreatic ductal adenocarcinoma.

April 27th 2020, 11:18pm

AACR Annual Meeting

Continuous dosing with dabrafenib and trametinib improved progression-free survival compared with intermittent dosing in patients with BRAF mutation–positive advanced melanoma.

April 11th 2020, 12:24am

SGO Annual Meeting

The success of frontline maintenance niraparib in the phase III PRIMA trial extends to meeting biomarker-defined and other secondary endpoints and showing positive patient-reported outcomes.

April 10th 2020, 10:14pm

SGO Annual Meeting

The addition of trastuzumab to carboplatin and paclitaxel resulted in a significant survival benefit in women with advanced or recurrent, HER2-positive uterine serous carcinoma, with the greatest benefit observed in those with stage III/IV disease who received the regimen up front.

April 10th 2020, 9:56pm

SGO Annual Meeting

David O'Malley, MD, discusses the increased benefit of rucaparib maintenance in patients with ovarian cancer who express RAD51C/D mutations.

April 10th 2020, 9:56pm

SGO Annual Meeting

Elizabeth M. Swisher, MD, discusses the implications of the phase III VELIA/GOG-3005 trial in ovarian cancer.

April 9th 2020, 11:54pm

SGO Annual Meeting

David O’Malley, MD, discusses the rationale to evaluate the clinical benefit of rucaparib maintenance treatment following disease progression in a subgroup of patients with ovarian cancer whose disease is associated with a mutation in a non-BRCA homologous recombination gene in the phase III ARIEL3 trial in ovarian cancer.

April 9th 2020, 11:18pm

SGO Annual Meeting

Amanda Nickles Fader, MD, discusses findings from a randomized phase II trial examining the efficacy of adding trastuzumab to carboplatin/paclitaxel in patients with advanced or recurrent uterine serous carcinomas that overexpress HER2/neu.

April 8th 2020, 9:14pm

SGO Annual Meeting

The combination of olaparib and bevacizumab was found to improve progression-free survival outcomes versus bevacizumab alone as a frontline maintenance treatment in patients with newly diagnosed advanced high-grade serous ovarian cancer, regardless of the timing of surgery or residual disease status after surgery.

April 8th 2020, 6:40pm

SGO Annual Meeting

The combination of niraparib and bevacizumab as a frontline maintenance therapy was found to have impressive clinical activity in patients with advanced ovarian cancer who had a complete or partial response to frontline platinum-based chemotherapy plus bevacizumab.

April 7th 2020, 7:47pm

SGO Annual Meeting

Trametinib monotherapy has emerged as a new treatment option for women with recurrent low-grade serous ovarian cancers based on improvements in survival outcomes and response rates demonstrated in a phase II/III study.

April 6th 2020, 11:37pm

SGO Annual Meeting

Adding veliparib to frontline induction chemotherapy increased complete and CA-125 responses compared with chemotherapy alone in patients with high-grade serous ovarian cancer, according to an exploratory analysis of the phase III VELIA trial.

April 4th 2020, 1:37am

SGO Annual Meeting

Dana Chase, MD, discusses niraparib as frontline maintenance therapy in ovarian cancer.

April 3rd 2020, 10:57pm

SGO Annual Meeting

Rucaparib was associated with superior outcomes among women with ovarian cancer harboring a non-BRCA homologous recombination repair gene mutation compared with placebo, according to an analysis of specimens collected in the phase III ARIEL3 trial (NCT01968213).